

GLAXOSMITHKLINE PLC  
Form 6-K  
February 19, 2019

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending 18 February 2019

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Mr N Hirons
  - b) Position/status SVP, Global Ethics and Compliance
  - c) Initial notification/ amendment Initial Notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 

Ordinary shares of 25 pence each ('Ordinary Shares')

a) Description of the financial instrument ISIN: GB0009252882

b) Nature of the transaction

The exercise of nil-cost options over Ordinary Shares granted on 11 February 2016 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.

c) Price(s) and volume(s)

Price(s)	Volume(s)
£0.0000	15,914 (Deferred)
£0.0000	9,392 (Matching)

Aggregated information

d) Aggregated volume 25,306

Price £0.0000

e) Date of the transaction 2019-02-15

f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Mr N Hirons
  - b) Position/status SVP, Global Ethics and Compliance
  - c) Initial notification/ amendment Initial Notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 

Ordinary shares of 25 pence each ('Ordinary Shares')

  - a) Description of the financial instrument ISIN: GB0009252882

The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 15 February 2019 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.

Price(s)	Volume(s)
£15.9006	7,500 (Deferred)
£15.9006	4,425 (Matching)

  - d) Aggregated information
  - d) Aggregated volume 11,925
  - Price £15.9006
  - e) Date of the transaction 2019-02-15
  - f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Mr D Redfern
  - b) Position/status Chief Strategy Officer
  - c) Initial notification/ amendment Initial Notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')

- a) Description of the financial instrument ISIN: GB0009252882

- b) Nature of the transaction
- The exercise of nil-cost options over Ordinary Shares granted on 11 February 2016 under the Company's 2009 Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.

- |                           | Price(s) | Volume(s)            |
|---------------------------|----------|----------------------|
| c) Price(s) and volume(s) | £0.0000  | 20,254<br>(Deferred) |
|                           | £0.0000  | 11,952<br>(Matching) |

- Aggregated information
- d) Aggregated volume 32,206
- Price £0.0000
- e) Date of the transaction 2019-02-15
- f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr D Redfern
- b) Position/status Chief Strategy Officer
- c) Initial notification/ amendment Initial Notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793

- Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence each ('Ordinary Shares')

- a) Description of the financial instrument ISIN: GB0009252882

- b) Nature of the transaction
- The sale of Ordinary Shares to meet tax liabilities on

nil-cost options over  
 Ordinary Shares exercised on  
 15 February 2019 under the  
 Company's Deferred Annual  
 Bonus Plan - Deferred Bonus  
 and Matching Awards.

c) Price(s) and volume(s)  
 Price(s) Volume(s)  
 £15.878 9,545 (Deferred)  
 £15.878 5,631 (Matching)

Aggregated information

d) Aggregated volume 15,176  
 Price £15.878  
 e) Date of the transaction 2019-02-15  
 f) Place of the transaction London Stock Exchange  
 (XLON)

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Ms C Thomas  
 b) Position/status SVP, Human Resources  
 c) Initial notification/ amendment Initial Notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

Ordinary shares of 25 pence  
 each ('Ordinary Shares')

a) Description of the financial instrument ISIN: GB0009252882

b) Nature of the transaction The exercise of nil-cost  
 options over Ordinary Shares  
 granted on 11 February 2016  
 under the Company's 2009  
 Deferred Annual Bonus Plan -  
 Deferred Bonus and Matching

		Awards.	
		Price(s)	Volume(s)
c) Price(s) and volume(s)		£0.0000	29,636 (Deferred)
		£0.0000	17,488 (Matching)
Aggregated information			
d) Aggregated volume		47,124	
Price		£0.0000	
e) Date of the transaction		2019-02-15	
f) Place of the transaction		n/a	

1. Details of PDMR/person closely associated with them ('PCA')
  - a) Name Ms C Thomas
  - b) Position/status SVP, Human Resources
  - c) Initial notification/ amendment Initial Notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
  - a) Name GlaxoSmithKline plc
  - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 

Ordinary shares of 25 pence each ('Ordinary Shares')

  - a) Description of the financial instrument ISIN: GB0009252882

- b) Nature of the transaction
 

The sale of Ordinary Shares to meet tax liabilities on nil-cost options over Ordinary Shares exercised on 15 February 2019 under the Company's Deferred Annual Bonus Plan - Deferred Bonus and Matching Awards.

		Price(s)	Volume(s)
c) Price(s) and volume(s)		£15.8753	13,951 (Deferred)
		£15.8753	8,232 (Matching)

Aggregated information	
d) Aggregated volume	22,183
Price	£15.8753
e) Date of the transaction	2019-02-15
f) Place of the transaction	London Stock Exchange (XLON)

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
(Registrant)

Date: February 18, 2019

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc